Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib+Bevacizumab+Carboplatin and Pemetrexed for Untreated EGFR-Mutated Advanced Non-squamous NSCLC
NCT05507606Phase 2Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Aug 2021
- Primary completion
- Aug 2023
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of osimertinib, bevacizumab, carboplatin, pemetrexed in non-small cell lung cancer (NSCLC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Status: unknown.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05507606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05507606.